AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer
AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.
Warngau, 15 March 2021
AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.
from left side to right side: Dr. Friedrich Tegel, Dr. Konstantin Petropoulos, Philipp Karbach
Dr. Petropoulos has more than ten years of experience in the pharmaceutical and biotechnology industry and distinguishes himself through success in various management positions.
His main focus was on corporate and business development, portfolio management as well as partnering and commercialization of innovative technologies and therapeutics in various indications. Prior to joining AMW, Dr. Petropoulos was Vice President Business Development, Marketing & Sales of Leukocare AG, a leading provider of formulation development services in the field of biopharmaceuticals. Previously, he was Head of Portfolio Operations & Analytics at Bayer AG and Head Pre-Commercial Group at MorphoSys, where he was instrumental in establishing first commercial structures for the launch preparation of the therapeutic antibody Monjuvi®.
“I am pleased to welcome Konstantin Petropoulos as the new CEO at AMW,” expressed Manfred Ulmer-Weber, partner at SHS Gesellschaft für Beteiligungsmanagement, on behalf of AMW’s shareholders. “He is an experienced and skilled manager who knows both the biotech and pharma perspectives very well and contributes deep expertise in business development as well as for building an R&D pipeline. With the already approved products of AMW, the expertise in the development and manufacturing of biodegradable slow release formulations has been proven during previous years. The aim now is to strengthen AMW’s global presence and further expand the R&D pipeline with both proprietary products and collaborations. Dr. Petropoulos will complement the existing management team to elevate the company to a new level.”
“I am very happy and honored to assume the position of CEO at AMW and greatly appreciate the trust that the shareholders have expressed in me,” stated Dr. Konstantin Petropoulos. In collaboration with my new colleagues, I will best apply AMW’s innovative technology platforms and long-term development expertise to provide better treatment solutions for patients around the world.”
About Konstantin Petropoulos
Dr. Konstantin Petropoulos has many years of experience in leadership positions in the biopharmaceutical and biotechnology industry. Before joining AMW, Dr. Petropoulos was Vice President Business Development, Marketing & Sales at Leukocare AG, a leading provider of formulation development services in the field of biopharmaceuticals. Previously, he was Head of Portfolio Operations & Analytics at Bayer and held various positions of increasing responsibility at MorphoSys; most recently as Head Pre-Commercial Group, where he was instrumental in establishing initial commercial structures for the launch preparation of the therapeutic antibody Monjuvi®. Dr. Petropoulos obtained a PhD in Molecular Biology from the Ludwig-Maximilians-University of Munich and a Master of Business Administration from the FOM Hochschule for economy and Management.
About AMW GmbH
AMW GmbH is a specialty pharmaceutical company specializing in novel drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or via patches (transdermal) or rings (vaginal). The company was founded in 2008 by Dr. Wilfried Fischer and develops therapeutic solutions in the fields of oncology, neurology, dermatology, pain therapy and ophthalmology.
AMW is based in Warngau, Upper Bavaria, about 40km south of Munich.